A deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and...

PARPi monotherapy has been a milestone in the management of many BRCA1/2-mutated cancers, offering patients and prescribers the hope of...

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic,...

Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways...

The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...

The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for...

ICER's expert group unanimously voted against Biogen's Aduhelm and its benefit for Alzheimer's patients. (Biogen) By Noah Higgins-Dunn |...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...

Kimberly Grant, PharmD, and Julia Mahler, PharmD, clinical pharmacists with IPD Analytics, state that specialty products are outpacing...

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...

With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...

As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...

In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...

The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...

An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.

Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.

Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.

Competitors in the field of adalimumab and insulin products may soon include authorized biologics.